All figures below come from Revolution Medicines’ official filings and press releases: the full-year 2024 results release (GlobeNewswire, 26 Feb 2025) and the Q3 2025 results release (GlobeNewswire, 5 Nov 2025), plus the Q3 2025 Form 10-Q.

Full-year 2024 revenue, losses, operating expenses and cash are from the FY24 press release (link, see “Full Year 2024 Financial Highlights”). Q3 2025 numbers (net loss 305.2 M USD, cash 1.93 B USD) and the updated 2025 GAAP net loss guidance 1.03–1.09 B USD are from the Q3 2025 press release (link, “Financial Highlights” and “Financial Guidance”). The share-count figure (189,231,562) is reported in the condensed consolidated statements of operations in the same press release and in the Form 10-Q filed 5 November 2025.

Revolution Medicines, Inc. (Nasdaq: RVMD) enters the 44th Annual J.P. Morgan Healthcare Conference as a late-stage, pre-commercial oncology company focused on RAS(ON) inhibitors. The company’s FY24 results release (link) positions RVMD as “a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers,” with a deep pipeline led by daraxonrasib, elironrasib and zoldonrasib.

From a financial standpoint, RVMD is still pre-revenue but heavily funded: 2024 revenue was zero, full-year net loss was 600.1 M USD, and cash/cash equivalents/marketable securities totaled 2.289 B USD at 31 December 2024. The Q3 2025 update (link) reports a Q3 2025 net loss of 305.2 M USD and confirms a 2025 GAAP net loss guidance of 1.03–1.09 B USD, with existing cash expected to fund operations into the second half of 2027.

On 8 January 2026, Revolution announced that the FDA has granted Breakthrough Therapy Designation (BTD) to zoldonrasib, its RAS(ON) G12D-selective inhibitor, for adult patients with KRAS G12D-mutated locally advanced or metastatic NSCLC previously treated with anti-PD-1/PD-L1 therapy and platinum-based chemotherapy (BTD press release). This is the first BTD for an investigational drug specifically targeting KRAS G12D in NSCLC.

In parallel, multiple outlets (Financial Times, Reuters, Barron’s) report that Merck is in advanced discussions to acquire Revolution Medicines for 28–32 B USD (Reuters, FT), while AbbVie has publicly denied earlier M&A rumors reported by the Wall Street Journal. These discussions are not final and may or may not result in a transaction.

Late-stage, pre-commercial RAS(ON) platform with multiple pivotal trials, a very strong cash position and fresh BTD for zoldonrasib – but also 600+ M USD annual losses, no product revenue yet, complex multi-trial execution, and M&A speculation that may not materialize. Information only, not a buy/sell view.

In its FY24 results and in the “About” sections of recent press releases (FY24 PR, Q3 2025 PR), RVMD describes itself as a late-stage clinical oncology company whose R&D pipeline “comprises RAS(ON) inhibitors designed to suppress diverse oncogenic variants of RAS proteins.”

The current clinical RAS(ON) portfolio includes:

• Daraxonrasib (RMC-6236) – a multi-selective RAS(ON) inhibitor.
• Elironrasib (RMC-6291) – G12C-selective RAS(ON) inhibitor.
• Zoldonrasib (RMC-9805) – G12D-selective RAS(ON) inhibitor (now with BTD in NSCLC G12D).
• RMC-5127 – G12V-selective RAS(ON) inhibitor expected to enter Phase 1 in 2026.
• Early programs RMC-0708 (Q61H) and RMC-8839 (G13C), described as “mutant-selective RAS(ON) inhibitors” in the FY24 press release.

RAS mutations are among the most frequent oncogenic drivers in human cancer; the company’s stated mission is “to revolutionize treatment for patients with RAS-addicted cancers through the discovery, development and delivery of innovative, targeted medicines across lines of therapy and tumor types” (FY24 PR, lines 11–13).

The FY24 and Q3 2025 releases give the most up-to-date official view of RVMD’s clinical programs (FY24 PR, Q3 2025 PR):

• Daraxonrasib – PDAC (pancreatic ductal adenocarcinoma)
  • Monotherapy Phase 1/1b data in previously treated PDAC were updated in the FY24 PR (lines 20–24): at 300 mg QD, median PFS was 8.8 months in KRAS G12X-mut PDAC and 8.5 months in all RAS-mut PDAC, with median OS not estimable and a manageable safety profile (TRAEs mainly rash and GI, mostly grade 1–2; no ≥G3 TRAEs in >10% of patients).
  • RASolute 302 – global Phase 3 daraxonrasib vs standard chemotherapy in 2L metastatic PDAC; FY24 PR (lines 60–61) says RVMD expects to substantially complete enrollment in 2025 to enable a readout in 2026; Q3 2025 PR (line 16) confirms enrollment is “winding down” and on track for 2026 data.
  • Two additional pivotal trials in earlier lines of PDAC (1L metastatic and adjuvant) are planned to start in 2H 2025 (FY24 PR lines 63–67; Q3 PR lines 20–23).
• Daraxonrasib – NSCLC
  • Updated Phase 1 data in RAS-mutant NSCLC were reported on 2 Dec 2024 and summarized in the FY24 PR (lines 34–36) as “favorable dose intensity and compelling PFS and OS,” supporting a Phase 3 design.
  • RASolve 301 – global randomized Phase 3 daraxonrasib vs docetaxel in previously treated RAS-mutant NSCLC; FY24 PR (lines 34–36) and Q3 PR (line 19) confirm that sites are being activated in the US, Europe and Japan.
  • Daraxonrasib + pembrolizumab combination data, reported 2 Dec 2024 (FY24 PR lines 41–43), support further evaluation of chemo-sparing regimens.
• Elironrasib (RMC-6291, G12C)
  • Elironrasib monotherapy data in G12C NSCLC previously treated with a KRAS G12C(OFF) inhibitor were presented at the Triple Meeting (Q3 2025 PR lines 27–28) and described as “encouraging” for response and PFS.
  • Combination trials include elironrasib + daraxonrasib in CRC post-G12C(OFF) and elironrasib + pembrolizumab in NSCLC, with early data indicating tolerability and supporting future triplets (FY24 PR lines 44–49).
• Zoldonrasib (RMC-9805, G12D)
  • First-in-human PDAC data, presented at the Triple Meeting and summarized in the FY24 PR (lines 27–30), showed “encouraging safety and antitumor activity” in RAS G12D-mutant PDAC.
  • On 8 January 2026, the FDA granted BTD to zoldonrasib for KRAS G12D-mut NSCLC 2L, as confirmed in Revolution’s BTD PR (link).
  • Zoldonrasib + daraxonrasib combination: FY24 PR (lines 52–53) notes that dose escalation is complete and the doublet is in expansion in solid tumors at anticipated Phase 2 doses.
• RMC-5127 and earlier programs
  • RMC-5127 (G12V) is expected to be “clinic-ready” in 2025 with a first-in-human Phase 1 in 2026 (FY24 PR lines 75–76; Q3 PR line 36).
  • RMC-0708 (Q61H) and RMC-8839 (G13C) remain in preclinical development; they are explicitly mentioned as mutant-selective RAS(ON) inhibitors in FY24 PR lines 106–107.

Official financials from FY24 and Q3 2025:

• 2024 total revenue: 0 USD (FY24 PR lines 93–95).
• R&D 2024: 592.2 M USD; G&A 97.3 M USD (FY24 PR lines 95–97).
• Net loss 2024: 600.1 M USD (FY24 PR line 98–100).
• Cash, cash equivalents and marketable securities 31/12/2024: 2.289 B USD (FY24 PR line 155).
• Q3 2025 net loss: 305.2 M USD; cash/cash equivalents/marketable securities 30/09/2025: 1.9315 B USD (Q3 2025 PR lines 45–50, 95–102).
• 2025 GAAP net loss guidance (updated): 1.03–1.09 B USD, including 115–130 M USD of non-cash stock-based compensation; current cash expected to fund operations into 2H 2027 (Q3 2025 PR lines 51–52, note “reiterates its full year 2025 GAAP net loss guidance of between $1.03 billion and $1.09 billion…”).

Questi numeri sono tutti riportati testualmente nei comunicati GlobeNewswire collegati sopra e nel Form 10-Q del 5 novembre 2025.

From the FY24 PR (lines 82–87, 155–159) and Q3 2025 PR (lines 45–52, 97–103):

• December 2024 equity offering: 823 M USD in net proceeds (FY24 PR line 82–83).
• Cash/securities 31/12/2024: 2.289 B USD; 30/09/2025: 1.9315 B USD.
• Working capital 31/12/2024: 2.1637 B USD; 30/09/2025: 1.7319 B USD.
• Total liabilities increased from 293.1 M USD (end 2024) to 655.0 M USD (Q3 2025), partially due to the Royalty Pharma monetization (Q3 PR line 46).
• Weighted-average basic/diluted shares 2024: 167.7 M; weighted-average basic/diluted shares 9M 2025: 188.7 M; common shares outstanding 30/09/2025: 189,231,562 (Q3 PR line 92, tables).

For trading metrics (price, market cap, volume), the most transparent way is to refer directly to live data sources rather than hardcoding values that will change:

• Latest stock quote and 52-week range → Yahoo Finance – RVMD
• Historical prices → RVMD historical data
• Market cap and recent move on takeover buzz → Barron’s piece on Merck/AbbVie takeover interest

Queste fonti riportano, tra l’altro, che la capitalizzazione di RVMD è arrivata intorno a 20,7 Mld USD durante la settimana dei rumor (dato Barron’s/Reuter), ma, proprio perché cambia in continuo, nel report non fissiamo un numero “definitivo” e rimandiamo direttamente ai link live.

I catalyst principali sono elencati nei PR ufficiali:

• JPM 2026 – Revolution Medicines ha annunciato che presenterà alla 44ª JPM il 12 gennaio 2026 (PR JPM, 5 gen 2026).
• RASolute 302 – Phase 3 PDAC 2L, arruolamento da completare nel 2025 e readout atteso nel 2026 (FY24 PR line 60–61; Q3 PR line 16).
• RASolve 301 – Phase 3 NSCLC RAS-mut pretrattato; attivazione siti in USA, EU, Giappone (FY24 PR 34–36; Q3 PR 19).
• Trial PDAC 1L e adiuvante – pianificati per il 2H 2025 (FY24 PR 63–67; Q3 PR 20–23).
• Zoldonrasib – ulteriore espansione clinica dopo BTD, con pianificazione di trial registrativi in PDAC 1L e combinazioni (FY24 PR 71–72; Q3 PR 31–32; BTD PR 8 gen 2026).
• RMC-5127 – ingresso in Fase 1 atteso nel 2026 (FY24 PR 75–76; Q3 PR 36).
• M&A – Reuters e FT riportano trattative in corso con Merck (Reuters, FT); l’esito (deal o no deal) è di per sé un catalyst.

• All core assets remain in development – no Phase 3 outcome yet.
• No product revenue; large guided GAAP loss for 2025 (1.03–1.09 B USD).
• Platform concentration on RAS(ON); negative safety/efficacy signals could affect multiple programs.
• Competition in KRAS/RAS from other pharma/biotechs pursuing G12C, G12D and other strategies.
• M&A negotiations may not result in a transaction; deal premium could unwind.

Based strictly on filings and official press releases, RVMD is:

• a late-stage RAS(ON) platform with three clinical pillars (daraxonrasib, elironrasib, zoldonrasib) and a clearly described pivotal strategy;
• a cash-rich, pre-commercial company burning hundreds of millions per year, with runway into 2H 2027 but no product revenue yet;
• a prime M&A candidate according to multiple reputable news outlets, with outcome still uncertain.

Questo report non è una raccomandazione di investimento, ma solo una sintesi ordinata di informazioni verificabili; per decisioni reali serve sempre ripartire dai documenti originali (10-K, 10-Q, 8-K e comunicati ufficiali).

Nature of the content. This article is for information and educational purposes only. It is based on publicly available sources such as SEC filings, the company’s investor-relations website and press releases, clinical-trial registries and reputable financial-information providers. Data may contain errors or become outdated; readers should always verify numbers and events directly from primary documents.

No investment advice. This report does not constitute, and must not be interpreted as, investment advice, individualized financial recommendation, solicitation or invitation to buy or sell financial instruments.

Risk warning. Late-stage, pre-commercial oncology companies are highly speculative and volatile. Anyone considering exposure to such instruments should evaluate their own objectives, risk tolerance and time horizon and, where appropriate, consult a qualified and regulated financial advisor.